
PepGen Inc (PEPG) Stock Forecast & Price Target
PepGen Inc (PEPG) Analyst Ratings
Bulls say
PepGen is a clinical-stage biotechnology company with a promising Enhanced Delivery Oligonucleotide platform that has shown potential in delivering oligonucleotide therapeutics to various target tissues. The company's financial results for the first quarter of 2026 show a positive trend and its cash reserves provide a promising runway for future developments. Despite minor adjustments to estimates, the company's target price is still high and maintains an Outperform rating, with the upcoming 10mg/kg PGN-EDODM1 data in the second half of 2026 being a key catalyst. However, potential challenges in financing, commercial execution, and competition, as well as safety concerns, should be monitored.
Bears say
PepGen is a clinical-stage biotechnology company that has developed an Enhanced Delivery Oligonucleotide platform for better delivery of therapeutics. Despite promising pipeline products, the company has a reported negative GAAP EPS and may struggle with obtaining funding and gaining regulatory approval. Additionally, early data on their lead product, PGN-EDODM1, is complicated and has shown some potential safety concerns. This, coupled with a decrease in fair value estimates from $9 to $5, indicates a negative outlook for PepGen's stock.
This aggregate rating is based on analysts' research of PepGen Inc and is not a guaranteed prediction by Public.com or investment advice.
PepGen Inc (PEPG) Analyst Forecast & Price Prediction
Start investing in PepGen Inc (PEPG)
Order type
Buy in
Order amount
Est. shares
0 shares